tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Evotec Biologics expands tech partnership with Sandoz

Evotec (EVO) announced that its biologics segment, Just – Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz (SDZNY). Just – Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025. This expanded partnership solidifies Just – Evotec Biologics’ commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. Sandoz secures further guarantees relating to long-term supply for patients with a reservation of significant commercial manufacturing capacity. Since May 2023, Just – Evotec Biologics and Sandoz have been engaged in a multi-year technology partnership aimed at the rapid development and manufacturing of biosimilars. Leveraging its data-driven, fully integrated design capability and continuous manufacturing technology platform, Just – Evotec Biologics aims to deliver the highest product quality and cost efficiency to its partners. This collaboration aligns with Evotec’s mission to improve access to medicines for patients across the globe.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1